• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
RZLT

RZLT

Rezolute, Inc.

NASDAQHealthcareBiotechnologyUS

USD4.58

+0.58 (+14.50%)

Rating:C+

Company Profile

CEO

Nevan Charles Elam

IPO Date

2013-01-14

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.37

Prev. Close

$4.00

Day Low

$4.07

Day High

$4.62

52W Low

$1.07

52W High

$11.46

Market Cap

$0.44B

Volume

5.21M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

7

Avg Positive

29.9%

Avg Negative

1.7%

Avg Neutral

68.6%

News Feed

Rezolute Added to Russell Microcap® Index

GlobeNewsWire·6/28/2021·↑ positive

RZLT Stock Price: Over 85% Increase Explanation

Pulse2·5/27/2021·↑ positive

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

GlobeNewsWire·5/20/2021·↑ positive

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

GlobeNewsWire·5/17/2021·↑ positive

Rezolute to Participate in Upcoming Investor Conferences in March

GlobeNewsWire·3/2/2021·↑ positive

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

GlobeNewsWire·2/10/2021·↓ negative

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

GlobeNewsWire·1/12/2021·↑ positive